MX384760B - Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. - Google Patents
Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.Info
- Publication number
- MX384760B MX384760B MX2018008286A MX2018008286A MX384760B MX 384760 B MX384760 B MX 384760B MX 2018008286 A MX2018008286 A MX 2018008286A MX 2018008286 A MX2018008286 A MX 2018008286A MX 384760 B MX384760 B MX 384760B
- Authority
- MX
- Mexico
- Prior art keywords
- gabapentin
- treatment
- active
- etianomer
- ketorolaco
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002870 gabapentin Drugs 0.000 title abstract 2
- 208000004296 neuralgia Diseases 0.000 title abstract 2
- 208000021722 neuropathic pain Diseases 0.000 title abstract 2
- 230000002195 synergetic effect Effects 0.000 title 1
- 208000001294 Nociceptive Pain Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229960004752 ketorolac Drugs 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
- 229960000281 trometamol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende la combinación sinérgica de un AINE, como lo es el principio activo: S-Ketorolaco de trometamina y un agente derivado GABA, como lo es el principio activo: gabapentina, los cuales se encuentran formulados con excipientes farmacéuticamente aceptables en una sola unidad de dosificación para ser administrado por vía oral, parenteral, tópica, transdérmica o por dispositivos para inhalación oral, nasal, misma que está indicada para el tratamiento del dolor neuropático y/o nociceptivo provocado por diversas etiologías.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2018008286A MX384760B (es) | 2018-07-04 | 2018-07-04 | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. |
| US15/734,068 US11510903B2 (en) | 2018-07-04 | 2019-06-05 | Synergic pharmaceutical composition of the active enantiomer (S)-ketorolac and Gabapentin for the treatment of neuropathic pain |
| PCT/MX2019/000064 WO2020009560A1 (es) | 2018-07-04 | 2019-06-05 | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático |
| CA3079509A CA3079509C (en) | 2018-07-04 | 2019-06-05 | Synergic drug combination of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain |
| EP19830351.3A EP3818981B1 (en) | 2018-07-04 | 2019-06-05 | Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain |
| CONC2020/0001887A CO2020001887A2 (es) | 2018-07-04 | 2020-02-20 | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2018008286A MX384760B (es) | 2018-07-04 | 2018-07-04 | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX384760B true MX384760B (es) | 2025-03-14 |
Family
ID=69060705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008286A MX384760B (es) | 2018-07-04 | 2018-07-04 | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11510903B2 (es) |
| EP (1) | EP3818981B1 (es) |
| CA (1) | CA3079509C (es) |
| CO (1) | CO2020001887A2 (es) |
| MX (1) | MX384760B (es) |
| WO (1) | WO2020009560A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388067B (es) * | 2019-07-16 | 2025-03-19 | Federico Amezcua Amezcua | Combinacion sinergica de s-ketorolaco y pregabalina en una composicion farmaceutica para el tratamiento del dolor neuropatico |
| CN113679676A (zh) * | 2020-05-19 | 2021-11-23 | 南京海融医药科技股份有限公司 | 一种左酮咯酸的药物组合物及其制备方法 |
| CN116999560A (zh) * | 2022-04-30 | 2023-11-07 | 武汉思瓴生物科技有限公司 | 可治疗疼痛的药物组合及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE69832712T2 (de) | 1997-09-08 | 2006-06-22 | Warner-Lambert Company Llc | Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7815936B2 (en) | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| EP2023898A1 (en) | 2006-05-10 | 2009-02-18 | Evonik Degussa GmbH | Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions |
| MX2007006091A (es) | 2007-05-21 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante. |
| MX366757B (es) | 2013-05-14 | 2019-07-23 | Laboratorio Raam De Sahuayo S A De C V | Sales del enantiomero activo s-ketorolaco. |
-
2018
- 2018-07-04 MX MX2018008286A patent/MX384760B/es unknown
-
2019
- 2019-06-05 US US15/734,068 patent/US11510903B2/en active Active
- 2019-06-05 EP EP19830351.3A patent/EP3818981B1/en active Active
- 2019-06-05 CA CA3079509A patent/CA3079509C/en active Active
- 2019-06-05 WO PCT/MX2019/000064 patent/WO2020009560A1/es not_active Ceased
-
2020
- 2020-02-20 CO CONC2020/0001887A patent/CO2020001887A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3079509A1 (en) | 2020-01-09 |
| US20210220330A1 (en) | 2021-07-22 |
| EP3818981B1 (en) | 2024-02-21 |
| EP3818981A4 (en) | 2022-04-20 |
| CO2020001887A2 (es) | 2020-04-01 |
| EP3818981C0 (en) | 2024-02-21 |
| US11510903B2 (en) | 2022-11-29 |
| EP3818981A1 (en) | 2021-05-12 |
| WO2020009560A1 (es) | 2020-01-09 |
| CA3079509C (en) | 2020-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| CO6251259A2 (es) | Formulaciones farmaceuticas de estriol en baja dosis | |
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| NZ737948A (en) | Orodispersible dosage unit containing an estetrol component | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| JP2016505050A5 (es) | ||
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты | |
| CO6270220A2 (es) | Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamotorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y el tratamiento de la gota artritis gotosa y enfermedades relacionadas | |
| MX2010011193A (es) | Composicion farmaceutica liquida para el tratamiento y prevencion del dolor. | |
| MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. | |
| MX2018011142A (es) | Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona. | |
| WO2020036478A3 (es) | Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor en las formas localizadas de afecciones reumáticas | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| GR1008819B (el) | Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου | |
| MX2019008467A (es) | Combinacion sinergica de s-ketorolaco y pregabalina en una composicion farmaceutica para el tratamiento del dolor neuropatico. | |
| CO6241114A2 (es) | Composicion farmaceutica que comprende la combinacion del agente antimicrobiano ciprofloxacino y el agente antioxidante acido ascorbico para el tratamiento de infecciones urinarias |